NASDAQ:INSMInsmed Stock Price, Forecast & News

Insmed's stock was trading at $21.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INSM stock has increased by 39.2% and is now trading at $29.57. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Insmed.

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Insmed.

Insmed Incorporated (NASDAQ:INSM) announced its quarterly earnings data on Thursday, April, 30th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.02. The biopharmaceutical company earned $36.90 million during the quarter, compared to analysts' expectations of $34.81 million. Insmed had a negative net margin of 162.82% and a negative return on equity of 87.35%. The firm's revenue was up 68.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.96) EPS. View Insmed's earnings history.

8 analysts have issued 1 year price targets for Insmed's stock. Their forecasts range from $20.00 to $56.00. On average, they anticipate Insmed's stock price to reach $42.00 in the next year. This suggests a possible upside of 42.0% from the stock's current price. View analysts' price targets for Insmed.

Media coverage about INSM stock has trended negative recently, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Insmed earned a coverage optimism score of -2.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Insmed.

Some companies that are related to Insmed include Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR) and Reata Pharmaceuticals (RETA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Geron (GERN), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Opko Health (OPK) and Amarin (AMRN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INSM stock can currently be purchased for approximately $29.57.

Insmed has a market capitalization of $2.99 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Insmed employs 373 workers across the globe.

The official website for Insmed is www.insmed.com.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]